U.K. Court Invalidates Merck Fosamax Patents

Law360, New York (November 6, 2003, 12:00 AM EST) -- The English Court of Appeal upheld the English Patents Court's ruling invalidating two Merck patents related to its Fosamax osteoporosis drug, Israeli generics drugmaker Teva Pharmaceutical Industries said Thursday.

One of the patents relates to pharmaceuticals containing the active ingredient of Merck's Fosamax and the second patent relates to its once-weekly administration, according to Teva.

Alendronate Sodium Tablets are the generic equivalent of Merck's Fosamax Tablets. The product is indicated for the treatment and prevention of osteoporosis and the treatment of Paget's disease.

Annual branded sales...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.